Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 6/20 | 0.64 |
| ▸ | CDK8 | P49336 | 3/20 | 0.64 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.64 |
| ▸ | SGK1 | O00141 | 5/20 | 0.56 |
| ▸ | CAMKK2 | Q96RR4 | 3/20 | 0.56 |
| ▸ | KIT | P10721 | 1/20 | 0.54 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.54 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.52 |
| ▸ | CLK1 | P49759 | 1/20 | 0.51 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.51 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.51 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26175448 | 0.90 | KIT (0.58) | AXLCDK8TNIKKITNTRK1 | |
| SCHEMBL26175287 | 0.87 | KIT (0.58) | AXLCDK8TNIKSGK1CAMKK2 | |
| SCHEMBL26175248 | 0.85 | AXL (0.65) | AXLCDK8TNIKSGK1CAMKK2 | |
| SCHEMBL26175333 | 0.84 | ALK (0.56) | TNIK | |
| SCHEMBL26175487 | 0.84 | TGFBR1 (0.47) | AXLCDK8TNIKCAMKK2KIT | |
| SCHEMBL26174654 | 0.83 | JAK2 (0.56) | AXLCDK8TNIKKITMAP3K11 | |
| SCHEMBL26174736 | 0.83 | PDE4A (0.45) | AXLCDK8TNIKKITMAP3K11 | |
| SCHEMBL26174699 | 0.83 | CYP1A2 (0.47) | AXLCDK8TNIKKITMAP3K11 | |
| SCHEMBL26175523 | 0.81 | NTRK1 (0.48) | AXLCDK8TNIKKITMAP3K11 | |
| SCHEMBL26174489 | 0.80 | CAMKK2 (0.51) | CAMKK2DYRK1ADYRK1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192686-A1 | 1H-PYRROLO[2,3-B]PYRIDINES AND PREPARATION AND USES THEREOF | TENARX, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230192686-A1 | 1H-PYRROLO[2,3-B]PYRIDINES AND PREPARATION AND USES THEREOF | TENARX, INC. | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192686-A1 | 1H-PYRROLO[2,3-B]PYRIDINES AND PREPARATION AND USES THEREOF | DYRK1A, DYRK1B, DYRK2 | AXL 1433/4885CDK8 485/4885TNIK 500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.